BR0215348A - Derivados de carbamato de 1-alquil-1-azoniabiciclo[2-2]octano e uso destes como antagonistas do receptor muscarìnico - Google Patents

Derivados de carbamato de 1-alquil-1-azoniabiciclo[2-2]octano e uso destes como antagonistas do receptor muscarìnico

Info

Publication number
BR0215348A
BR0215348A BR0215348-3A BR0215348A BR0215348A BR 0215348 A BR0215348 A BR 0215348A BR 0215348 A BR0215348 A BR 0215348A BR 0215348 A BR0215348 A BR 0215348A
Authority
BR
Brazil
Prior art keywords
alkyl
octane
receptor antagonists
receptor
cycloalkyl
Prior art date
Application number
BR0215348-3A
Other languages
English (en)
Inventor
Juan Lorenzo Catena Ruiz
Carles Ferrerons Gallemi
Anna Fernandez Serrat
Ignacio Jose Miquel Bono
Dolors Balsa Lopez
Carmen Lagunas Arnal
Carolina Salcedo Roca
Natividad Toledo Mesa
Andres Fernandez Garcia
Original Assignee
S A L V A T Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S A L V A T Lab Sa filed Critical S A L V A T Lab Sa
Publication of BR0215348A publication Critical patent/BR0215348A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine

Abstract

"DERIVADOS DE CARBANATO DE 1-ALQUIL-1-AZONIABICICLO[2.2]OCTANO E USO DESTES COMO ANTAGONISTAS DO RECEPTOR MUSCARìNIO". Refere-se o presente invento a carbamatos de fórmula geral (I): em que R1, R2 e R3 são H, OH, NO~ 2~, SH, CN, F, Cl, Br, I, COOH, CONH~ 2~, (C~1-~C~ 4~)alquiloxicarbonila, (C~ 1~-C~ 4~)alquilsulfanila, (C~ 1-C~ 4~)alquilsulfinila, (C~ 1~-C~ 4~)alquilsulfonila, (C~ 1~-C~ 4~)alcoxila opcionalmente substituído com um ou vários F, e (C~ 1~-C~ 4~)alquila opcionalmente substituído com um ou vários F ou OH; R4 é cicloalquila, fenila, heteroarila ou um sistema de anéis bicíclico; R5 é uma cicloalquila, (C~ 5~-C~ 10~)-alquila, ou uma (C~ 1~-C~ 10~)alquila substituída; e X^ - ^ é um ânion fisiologicamente aceito. O carbamato (I) é um antagonista seletivo ao receptor M~ 3~ versus o receptor M~ 2~ e pode ser usado para o tratamento de incontinência urinária (particularmente, aquela causada por uma bexiga sobreativa), síndrome do intestino irritável, e desordens respiratórias (particularmente, doenças pulmonares obstrutivas crónicas, bronquite crónica, asma, enfisema e rinite), bem como em intervenções oftálmicas.
BR0215348-3A 2001-12-20 2002-12-18 Derivados de carbamato de 1-alquil-1-azoniabiciclo[2-2]octano e uso destes como antagonistas do receptor muscarìnico BR0215348A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200200043 2001-12-20
PCT/EP2002/014470 WO2003053966A2 (en) 2001-12-20 2002-12-18 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
BR0215348A true BR0215348A (pt) 2004-11-16

Family

ID=32480019

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215348-3A BR0215348A (pt) 2001-12-20 2002-12-18 Derivados de carbamato de 1-alquil-1-azoniabiciclo[2-2]octano e uso destes como antagonistas do receptor muscarìnico

Country Status (21)

Country Link
US (1) US7452904B2 (pt)
EP (1) EP1461336B1 (pt)
JP (1) JP4505227B2 (pt)
KR (1) KR100944580B1 (pt)
CN (1) CN1832948B (pt)
BR (1) BR0215348A (pt)
CA (1) CA2470956C (pt)
EA (1) EA006505B1 (pt)
ES (1) ES2425347T3 (pt)
GE (1) GEP20063958B (pt)
HK (1) HK1070057A1 (pt)
HR (1) HRP20040661A2 (pt)
HU (1) HUP0500107A3 (pt)
IL (1) IL162596A0 (pt)
MA (1) MA26385A1 (pt)
MX (1) MXPA04006206A (pt)
NO (1) NO329664B1 (pt)
PL (1) PL211250B1 (pt)
RS (1) RS52522B (pt)
UA (1) UA76571C2 (pt)
WO (1) WO2003053966A2 (pt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100751981B1 (ko) * 2000-06-27 2007-08-28 라보라토리오스 살바트, 에스.에이. 아릴알킬아민으로부터 유도된 카바메이트
CA2441896A1 (en) 2000-12-22 2002-07-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
AR044134A1 (es) 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
ATE435862T1 (de) 2003-05-28 2009-07-15 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
UY28871A1 (es) * 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
EP1747219A4 (en) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
CN101048367A (zh) 2004-07-30 2007-10-03 萨尔瓦特实验室股份有限公司 作为PPARγ调节剂的新的酪氨酸衍生物
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1928821B1 (en) 2005-09-21 2009-01-07 Pfizer Limited Carboxamide derivatives as muscarinic receptor antagonists
EP2532678A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2013211E (pt) 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
EP1882691A1 (en) * 2006-07-26 2008-01-30 CHIESI FARMACEUTICI S.p.A. Quinuclidine derivatives as M3 antagonists
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
WO2008041184A2 (en) * 2006-10-03 2008-04-10 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2008085608A1 (en) 2007-01-10 2008-07-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
PL2155721T3 (pl) 2007-05-07 2011-07-29 Novartis Ag Związki organiczne
EP2065385A1 (en) 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
EP2080507A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulations comprising an anticholinergic drug
EP2080523A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
EP2080508A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
BRPI0915018A2 (pt) 2008-06-10 2015-10-27 Novartis Ag compostos orgânicos
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
EP2206712A1 (en) 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MX2012002066A (es) 2009-08-17 2012-03-29 Intellikine Inc Compuestos heterociclicos y usos de los mismos.
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
CN102946868B (zh) 2010-06-22 2014-10-29 奇斯药制品公司 包含抗毒蕈碱药的干粉制剂
EP2585458B1 (en) 2010-06-22 2015-01-07 Chiesi Farmaceutici S.p.A. Alkaloid aminoester derivatives and medicinal compositions thereof
EP2585457B1 (en) * 2010-06-22 2015-07-22 Chiesi Farmaceutici S.p.A. Alkaloid aminoester derivatives and medicinal composition thereof
RU2580835C2 (ru) * 2010-06-22 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Алкалоидные производные на основе сложных аминоэфиров и композиции лекарственных средств, содержащие их
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
DK2881392T3 (en) * 2010-11-16 2018-07-23 Texas Heart Inst Agonists that enhance the binding of integrin-expressing cells to integrin receptors
KR20130141534A (ko) 2010-11-26 2013-12-26 키에시 파르마슈티시 엣스. 피. 에이. 글리신 유도체 및 무스카린 수용체 길항제로서의 이들의 용도
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US20120220557A1 (en) 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
EP2702041A1 (en) 2011-04-29 2014-03-05 Chiesi Farmaceutici S.p.A. Alkaloid ester and carbamate derivatives and medicinal compositions thereof
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
CA2862008A1 (en) 2011-12-30 2013-07-04 Chiesi Farmaceutici S.P.A. Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
EA032075B1 (ru) 2014-04-24 2019-04-30 Новартис Аг Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
CA2945257A1 (en) 2014-04-24 2015-10-29 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
RU2695230C2 (ru) 2014-07-31 2019-07-22 Новартис Аг Сочетанная терапия
CA2984316A1 (en) * 2015-04-29 2016-11-03 Darren G. Woodside Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants
US11311619B2 (en) 2016-04-28 2022-04-26 7 Hills Pharma Inc. and Texas Heart Institute Integrin activator vaccine compositions
CN113891744A (zh) 2019-06-10 2022-01-04 诺华股份有限公司 用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物
EP4021572A1 (en) 2019-08-28 2022-07-06 Novartis AG Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0495071A (ja) * 1990-08-10 1992-03-27 Kyorin Pharmaceut Co Ltd カルバミン酸誘導体
WO1995006635A1 (fr) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
KR970701174A (ko) * 1994-02-10 1997-03-17 오노다 마사요시 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
WO2001042212A1 (en) * 1999-12-07 2001-06-14 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity
KR100751981B1 (ko) * 2000-06-27 2007-08-28 라보라토리오스 살바트, 에스.에이. 아릴알킬아민으로부터 유도된 카바메이트
CA2441896A1 (en) * 2000-12-22 2002-07-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists

Also Published As

Publication number Publication date
PL211250B1 (pl) 2012-04-30
HRP20040661A2 (en) 2005-06-30
AU2002361158A1 (en) 2003-07-09
IL162596A0 (en) 2005-11-20
JP4505227B2 (ja) 2010-07-21
HUP0500107A2 (hu) 2005-05-30
NO329664B1 (no) 2010-11-29
CA2470956C (en) 2011-08-02
RS52522B (en) 2013-04-30
US7452904B2 (en) 2008-11-18
HK1070057A1 (pt) 2005-06-10
GEP20063958B (en) 2006-11-10
CN1832948A (zh) 2006-09-13
KR100944580B1 (ko) 2010-02-25
WO2003053966A2 (en) 2003-07-03
HUP0500107A3 (en) 2011-05-30
KR20040091614A (ko) 2004-10-28
ES2425347T3 (es) 2013-10-14
RS53904A (en) 2006-12-15
WO2003053966A8 (en) 2004-06-24
NO20043064L (no) 2004-09-17
PL370972A1 (en) 2005-06-13
EP1461336B1 (en) 2013-05-22
EA006505B1 (ru) 2005-12-29
EA200400832A1 (ru) 2004-12-30
JP2005516954A (ja) 2005-06-09
UA76571C2 (en) 2006-08-15
CN1832948B (zh) 2011-06-15
EP1461336A2 (en) 2004-09-29
US20050043349A1 (en) 2005-02-24
MXPA04006206A (es) 2004-12-06
WO2003053966A3 (en) 2003-11-13
MA26385A1 (fr) 2004-11-01
CA2470956A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
BR0215348A (pt) Derivados de carbamato de 1-alquil-1-azoniabiciclo[2-2]octano e uso destes como antagonistas do receptor muscarìnico
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
NO20045219L (no) Kalsitonin-gen-relaterte peptid-reseptor-antagonister
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
BRPI0514661B8 (pt) antagonistas de vasopressina v1a, composição farmacêutica e uso dos referidos antagonistas
WO2006023460A3 (en) COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
UA99309C2 (ru) Замещенные пиперидинодигидротиенопиримидины
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
GEP20104973B (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
EA200701361A1 (ru) Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ
BG66102B1 (bg) Карбаматни производни на арилалкиламини
TW200626142A (en) Chemical compounds
MX2009011812A (es) Aminopirimidinas utiles como inhibidores de cinasa.
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
JO2527B1 (en) Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines
WO2006002434A3 (en) Novel indazole carboxamides and their use
ATE446089T1 (de) 2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika
NZ595433A (en) 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2
EA200701879A1 (ru) Замещённые производные оксадиазаспиро [5.5] ундеканона и их применение в качестве антагонистов нейрокинина
MY147474A (en) 1-[(4-[benzoyl(methyl)amino]-3-(phenyl)butyl]azetidine derivatives for the treatment of gastrointestinal disorders 1
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung
EA200800071A1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: LABORATORIOS S.A.L.V.A.T., S.A. (ES)

Free format text: A FIM DE ATENDER O SOLICITADO NA PETICAO DE TRANSFERENCIA NO 018060054717/SP DE 30/05/2006, QUEIRAREAPRESENTAR O DOCUMENTO DE CESSAO DEVIDAMENTE ASSINADO POR DUAS TESTEMUNHAS.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: LABORATORIOS S.A.L.V.A.T., S.A. (ES)

Free format text: REFERENTE A RPI 1861 DE 05/09/2006 COD. (25.3), POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: CHIESI FARMACEUTICI S.P.A. (IT)

Free format text: TRANSFERIDO DE: LABORATORIOS S.A.L.V.A.T., S.A.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2285 DE 21/10/2014.